ZS Genetics Contributes Chapter In New Book From Wiley -
Next Generation Genome Sequencing: Towards Personalized Medicine
North Reading, MA – November 30, 2008 – Informational release.
ZS Genetic’s unique methodology for performing genetic sequencing has been included in the new book by Dr. Michal Janitz of the Max Planck Institute for Molecular Genetics, Next Generation Genome Sequencing: Towards Personalized Medicine, published by Wiley-Blackwell.
Dr. Janitz contacted ZS Genetics requesting that the company contribute a chapter about ZS Genetics’ Third Generation approach to sequencing for his book on available and emerging sequencing technologies. William R. Glover, III and Dr. W. Kelley Thomas contributed the chapter – “Direct Sequencing by TEM of Z-Substituted DNA Molecules” (Chapter 9) - which appears in the book.
More information on the publication can be found here.
ISBN: 978-3-527-32090-5
Hardcover
282 pages
November 2008
From the book jacket:
Written by leading experts from industry and academia, this first single comprehensive resource addresses recent developments in next generation DNA sequencing technology and their impact on genome research, drug discovery and health care. As such, it presents a detailed comparative analysis of commercially available platforms as well as insights into alternative, emerging sequencing techniques. In addition, the book not only covers the principles of DNA sequencing techniques but also social and ethical aspects, the concept of personalized medicine and a five-year perspective of DNA sequencing.
About ZS Genetics
ZS Genetics is a privately held company based in the northeastern USA that is finalizing development of a technology platform for directly creating detailed images of individual DNA or RNA molecules, using modified transmission electron microscopes and atomic labeling. ZS Genetics’ technology offers the prospect of revolutionary advancements in genetic analysis, with applications in the sequencing, expression and diagnostics markets. The technology shows the promise of sequencing whole human genomes in days instead of months, for thousands of dollars instead of millions; and with long base pair read-lengths, which allow the detection of long repeating patterns in a genetic code. The technology could change the multi-billion-dollar marketplace dynamics for genetic information applications, including enabling widespread adoption of genetics-based medicine, and driving important innovation in disease research, drug discovery, forensics, environmental impact studies, agriculture, anthropology and history.
Contact:
ZS Genetics, Inc.
Thomas D. Abert
603.847.9143
tda@zsgenetics.com
www.zsgenetics.com